| PEB0228 | High abstinence rates from a smoking cessation program embedded within an HIV clinic | E-poster | B29 |
| PEB0229 | The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) | E-poster | B30 |
| PEB0230 | Very high baseline HIV viremia impairs efficacy of NNRTI-based ART: A long-term observation in treatment-naïve patients | E-poster | B30 |
| PEB0231 | CD4:CD8 ratio normalization with modern antiretroviral regimens | E-poster | B30 |
| PEB0232 | Second-line dolutegravir or protease inhibitor for adults with HIV in rural Haiti with virologic failure on a first-line NNRTI-based regimen without available genotype | E-poster | B30 |
| PEB0233 | Weight change among treatment naive women initiating dolutegravir in the ARIA study | E-poster | B30 |
| PEB0234 | Clinical outcomes of heavily treatment experienced individuals in the OPERA Cohort | E-poster | B31 |
| PEB0235 | Real life study with dual therapy in a HIV-1 treatment experienced Portuguese cohort | E-poster | B32 |
| PEB0236 | Persons Living With HIV (PLWH) in Japan on 2-drug regimen reveal more complex patient profiles than that of a 3-drug regimen cohort | E-poster | B32 |
| PEB0237 | Durability of dual antiretroviral regimens and factors associated with discontinuation in the clinical practice | E-poster | B32 |